T0	Outcomes 329 379	accelerated development of cardiovascular disease.
T1	Outcomes 543 558	LDL cholesterol
T2	Outcomes 1628 1673	change in ultracentrifugation LDL cholesterol
T3	Outcomes 2074 2117	reduced ultracentrifugation LDL cholesterol
T4	Outcomes 2165 2175	p<0Â·0001).
T5	Outcomes 2176 2202	Treatment-emergent adverse
T6	Outcomes 2371 2414	and no anti-evolocumab antibody development
T7	Outcomes 2640 2658	was well tolerated
T8	Outcomes 2677 2700	reduced LDL cholesterol